Axsome: Axsome Therapeutics Lower Dose Of Attention Deficient Disorder Candidate Hits Primary Goal
Axsome's solriamfetol met primary and key secondary endpoints in a Phase 3 ADHD trial, showing significant symptom reduction and a favorable safety profile. read more
Read full article »
Axsome is a New York-based biopharmaceutical company that researches and develops novel therapies for the treatment of central nervous system disorders.
Read more